Development and characterisation of monoclonal antibodies specific for the murine inhibitory FcγRIIB (CD32B)

European Journal of Immunology

Volumn 42, Issue 8, 2012, Pages 2109-2120

  Williams, Emily L ^a   Tutt, Alison L ^a   French, Ruth R ^a   Chan, H T Claude ^a   Lau, Betty ^a   Penfold, Christine A ^a   Mockridge, C Ian ^a   Roghanian, Ali ^a   Cox, Kerry L ^a   Verbeek, J Sjef ^b   Glennie, Martin J ^a   Cragg, Mark S ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antibodies; Cancer; CD32B; Fc gamma RIIB; Immunotherapy

Indexed keywords

FC GAMMA RECEPTOR IIB MONOCLONAL ANTIBODY; FC RECEPTOR IIB; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ASSAY; BINDING AFFINITY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG RECEPTOR BINDING; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL DEATH; CELLS, CULTURED; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; PHOSPHORYLATION; RECEPTORS, IGG;

EID: 84864751569     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201142302     Document Type: Article

References (47)

1. Nimmerjahn, F. and Ravetch, J. V., Fc gamma receptors as regulators of immune responses. Nat. Rev. Immunol. 2008. 8: 34-47.
2. Ravetch, J. V. and Bolland, S., IgG Fc receptors. Annu. Rev. Immunol. 2001. 19: 275-290.
3. Nimmerjahn, F. and Ravetch, J. V., Fc-receptors as regulators of immunity. Adv. Immunol. 2007. 96: 179-204.
4. Nimmerjahn, F. and Ravetch, J. V., Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 2005. 310: 1510-1512.
5. Nimmerjahn, F. and Ravetch, J. V., Fcgamma receptors: old friends and new family members. Immunity 2006. 24: 19-28.
6. Clynes, R. A., Towers, T. L., Presta, L. G. and Ravetch, J. V., Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 2000. 6: 443-446.
7. Fossati-Jimack, L., Ioan-Facsinay, A., Reininger, L., Chicheportiche, Y., Watanabe, N., Saito, T., Hofhuis, F. M. et al., Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fc gamma receptor III. J. Exp. Med. 2000. 191: 1293-1302.
8. Floto, R. A., Clatworthy, M. R., Heilbronn, K. R., Rosner, D. R., MacAry, P. A., Rankin, A., Lehner, P. J. et al., Loss of function of a lupus-associated Fc gammaRIIb polymorphism through exclusion from lipid rafts. Nat. Med. 2005. 11: 1056-1058.
9. Kono, H., Kyogoku, C., Suzuki, T., Tsuchiya, N., Honda, H., Yamamoto, K., Tokunaga, K. et al., FcgammaRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. Hum. Mol. Genet. 2005. 14: 2881-2892.
10. Clynes, R., Takechi, Y., Moroi, Y., Houghton, A. and Ravetch, J. V., Fc receptors are required in passive and active immunity to melanoma. Proc. Natl. Acad. Sci. USA 1998. 95: 652-656.
11. Beers, S. A., French, R. R., Chan, H. T., Lim, S. H., Jarrett, T. C., Vidal, R. M., Wijayaweera, S. S. et al., Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 115: 5191-5201.
12. Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P. and Watier, H., Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002. 99: 754-758.
13. Weng, W. K. and Levy, R., Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 2003. 21: 3940-3947.
14. Ono, M., Bolland, S., Tempst, P. and Ravetch, J. V., Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc(gamma)RIIB. Nature 1996. 383: 263-266.
15. Liu, Q., Oliveira-Dos-Santos, A. J., Mariathasan, S., Bouchard, D., Jones, J., Sarao, R., Kozieradzki, I. et al., The inositol polyphosphate 5-phosphatase ship is a crucial negative regulator of B cell antigen receptor signaling. J. Exp. Med. 1998. 188: 1333-1342.
16. Ravetch, J. V. and Lanier, L. L., Immune inhibitory receptors. Science 2000. 290: 84-89.
17. Bolland, S., Pearse, R. N., Kurosaki, T. and Ravetch, J. V., SHIP modulates immune receptor responses by regulating membrane association of Btk. Immunity 1998. 8: 509-516.
18. Tamir, I., Stolpa, J. C., Helgason, C. D., Nakamura, K., Bruhns, P., Daeron, M. and Cambier, J. C., The RasGAP-binding protein p62dok is a mediator of inhibitory FcgammaRIIB signals in B cells. Immunity 2000. 12: 347-358.
19. Aman, M. J., Lamkin, T. D., Okada, H., Kurosaki, T. and Ravichandran, K. S., The inositol phosphatase SHIP inhibits Akt/PKB activation in B cells. J. Biol. Chem. 1998. 273: 33922-33928.
20. Jacob, A., Cooney, D., Tridandapani, S., Kelley, T. and Coggeshall, K. M., FcgammaRIIb modulation of surface immunoglobulin-induced Akt activation in murine B cells. J. Biol. Chem. 1999. 274: 13704-13710.
21. Yamanashi, Y., Tamura, T., Kanamori, T., Yamane, H., Nariuchi, H., Yamamoto, T. and Baltimore, D., Role of the rasGAP-associated docking protein p62(dok) in negative regulation of B cell receptor-mediated signaling. Genes Dev. 2000. 14: 11-16.
22. Brown, K. S., Blair, D., Reid, S. D., Nicholson, E. K. and Harnett, M. M., FcgammaRIIb-mediated negative regulation of BCR signalling is associated with the recruitment of the MAPkinase-phosphatase, Pac-1, and the 3'-inositol phosphatase, PTEN. Cell Signal 2004. 16: 71-80.
23. Tzeng, S. J., Bolland, S., Inabe, K., Kurosaki, T. and Pierce, S. K., The B cell inhibitory Fc receptor triggers apoptosis by a novel c-Abl family kinase-dependent pathway. J. Biol. Chem. 2005. 280: 35247-35254.
24. Pearse, R. N., Kawabe, T., Bolland, S., Guinamard, R., Kurosaki, T. and Ravetch, J. V., SHIP recruitment attenuates Fc gamma RIIB-induced B cell apoptosis. Immunity 1999. 10: 753-760.
25. Xiang, Z., Cutler, A. J., Brownlie, R. J., Fairfax, K., Lawlor, K. E., Severinson, E., Walker, E. U. et al., FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis. Nat. Immunol. 2007. 8: 419-429.
26. Unkeless, J. C., Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J. Exp. Med. 1979. 150: 580-596.
27. Tartour, E., de la Salle, H., de la Salle, C., Teillaud, C., Camoin, L., Galinha, A., Latour, S. et al., Identification, in mouse macrophages and in serum, of a soluble receptor for the Fc portion of IgG (Fc gamma R) encoded by an alternatively spliced transcript of the Fc gamma RII gene. Int. Immunol. 1993. 5: 859-868.
28. Miettinen, H. M., Matter, K., Hunziker, W., Rose, J. K. and Mellman, I., Fc receptor endocytosis is controlled by a cytoplasmic domain determinant that actively prevents coated pit localization. J. Cell Biol. 1992. 116: 875-888.
29. Chacko, G. W., Tridandapani, S., Damen, J. E., Liu, L., Krystal, G. and Coggeshall, K. M., Negative signaling in B lymphocytes induces tyrosine phosphorylation of the 145-kDa inositol polyphosphate 5-phosphatase, SHIP. J. Immunol. 1996. 157: 2234-2238.
30. Schmidt, E. V., Pattengale, P. K., Weir, L. and Leder, P., Transgenic mice bearing the human c-myc gene activated by an immunoglobulin enhancer: a pre-B-cell lymphoma model. Proc. Natl. Acad. Sci. USA 1988. 85: 6047-6051.
31. Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D. et al., The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985. 318: 533-538.
32. Ivanov, A., Beers, S. A., Walshe, C. A., Honeychurch, J., Alduaij, W., Cox, K. L., Potter, K. N. et al., Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J. Clin. Invest. 2009. 119: 2143-2159.
33. Ashman, R. F., Peckham, D. and Stunz, L. L., Fc receptor off-signal in the B cell involves apoptosis. J. Immunol. 1996. 157: 5-11.
34. Ashman, R. F., Peckham, D. and Stunz, L. L., Regulation of B cell apoptosis. Adv. Exp. Med. Biol. 1996. 406: 145-154.
35. Di Virgilio, F., Meyer, B. C., Greenberg, S. and Silverstein, S. C., Fc receptor-mediated phagocytosis occurs in macrophages at exceedingly low cytosolic Ca2+ levels. J. Cell Biol. 1988. 106: 657-666.
36. Brauweiler, A. M. and Cambier, J. C., Fc gamma RIIB activation leads to inhibition of signalling by independently ligated receptors. Biochem. Soc. Trans. 2003. 31: 281-285.
37. Kato, I., Takai, T. and Kudo, A., The pre-B cell receptor signaling for apoptosis is negatively regulated by Fc gamma RIIB. J. Immunol. 2002. 168: 629-634.
38. Fournier, E. M., Siberil, S., Costes, A., Varin, A., Fridman, W. H., Teillaud, J. L. and Sautes-Fridman, C., Activation of human peripheral IgM+ B cells is transiently inhibited by BCR-independent aggregation of Fc gammaRIIB. J. Immunol. 2008. 181: 5350-5359.
39. Rankin, C. T., Veri, M. C., Gorlatov, S., Tuaillon, N., Burke, S., Huang, L., Inzunza, H. D. et al., CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma. Blood 2006. 108: 2384-2391.
40. Beers, S. A., Chan, C. H., James, S., French, R. R., Attfield, K. E., Brennan, C. M., Ahuja, A. et al., Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood 2008. 112: 4170-4177.
41. Harris, A. W., Pinkert, C. A., Crawford, M., Langdon, W. Y., Brinster, R. L. and Adams, J. M., The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J. Exp. Med. 1988. 167: 353-371.
42. Illidge, T., Honeychurch, J., Howatt, W., Ross, F., Wilkins, B. and Cragg, M., A new in vivo and in vitro B cell lymphoma model, pi-BCL1. Cancer Biother Radiopharm. 2000. 15: 571-580.
43. Happo, L., Cragg, M. S., Phipson, B., Haga, J. M., Jansen, E. S., Herold, M. J., Dewson, G. et al., Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim. Blood 2010. 116: 5256-5267.
44. Elliott, T. J., Glennie, M. J., McBride, H. M. and Stevenson, G. T., Analysis of the interaction of antibodies with immunoglobulin idiotypes on neoplastic B lymphocytes: implications for immunotherapy. J. Immunol. 1987. 138: 981-988.
45. Tutt, A. L., French, R. R., Illidge, T. M., Honeychurch, J., McBride, H. M., Penfold, C. A., Fearon, D. T. et al., Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors. J. Immunol. 1998. 161: 3176-3185.
46. Walshe, C. A., Beers, S. A., French, R. R., Chan, C. H., Johnson, P. W., Packham, G. K., Glennie, M. J. et al., Induction of cytosolic calcium flux by CD20 is dependent upon B cell antigen receptor signaling. J. Biol. Chem. 2008. 283: 16971-16984.
47. Cragg, M. S., Zhang, L., French, R. R. and Glennie, M. J., Analysis of the interaction of monoclonal antibodies with surface IgM on neoplastic B-cells. Br. J. Cancer 1999. 79: 850-857.